[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aphrodite-group\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aphrodite-group":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634509","gonadotropin-therapy-in-idiopathic-hypogonadal-non-obstructive-100634509",false,"NCT07540611","Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive","\"Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive Azoospermia (APHRODITE Groups 3-4): A Multicenter Randomized Controlled Trial\"","GTIHNO","Inclusion Criteria:\n\n\\- Idiopathic NOA; hypogonadal (TT \\\u003C350 ng\u002FdL on two fasting morning tests); FSH ≥7.6 IU\u002FL (APHRODITE Group 3: 7.6-12.0 IU\u002FL; Group 4: \\>12.0 IU\u002FL).\n\nExclusion Criteria:\n\ncryptorchidism, chemo\u002Fradiation, genetic NOA (e.g., AZFa\u002Fcomplete AZFb), testicular trauma\u002Ftorsion, post-orchitis. prior micro-TESE within 12 months; recent gonadotropin therapy (\\\u003C6 months); uncontrolled endocrine disease; active malignancy; severe liver disease; polycythemia (Hct\\>50%); inability to comply. Varicocele\\>= Grade 3",true,"MALE",{"count":20,"type":21},860,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine whether short-term gonadotropin therapy (hCG + FSH) can increase sperm availability for ICSI in men with idiopathic non-obstructive azoospermia (NOA) and hypogonadism. The main questions it aims to answer are:\n\nDoes hormonal optimization improve the likelihood of obtaining usable sperm (via ejaculate or micro-TESE) by Week 16? Does hormonal therapy reduce the need for micro-TESE or improve downstream embryological and clinical outcomes?\n\nBecause there is a comparison group, researchers will compare hCG + FSH hormonal therapy with standard-of-care (no gonadotropins) to see if hormonal optimization increases sperm retrieval success and decreases surgical reliance.\n\nParticipants will:\n\nUndergo baseline hormonal and semen testing Be randomized to either hormonal therapy or standard-of-care If in the hormonal arm: receive hCG and FSH with monthly dose titration and aromatase inhibitors if indicated Provide semen samples at Weeks 12 and 16 Undergo micro-TESE if no ejaculated sperm are found (timing per protocol) Complete safety assessments and follow-up through Week 16",[27],"APHRODITE Group",[29,30,31,32],"Non-obstructive azoospermia (NOA)","Idiopathic NOA","Male infertility","Hypogonadism","NOT_YET_RECRUITING","2026-04-14",{"date":36,"type":37},"2026-04-20","ACTUAL",{"date":39,"type":21},"2026-07-17",{"date":41,"type":21},"2027-07-17",{"name":43,"class":44},"Indira IVF Hospital Pvt Ltd","OTHER",8]